Literature DB >> 21620110

Liver transplantation for acute liver failure: the Hungarian experience.

B Nemes1, G Zádori, D Görög, I Fehérvári, L Kóbori, R M Langer.   

Abstract

Acute liver failure (ALF) counts for 9%-11% of activity in leading liver transplant programs. We have summarized the Hungarian Liver Transplant Program experience for ALF among 412 consecutive orthotopic liver transplantations (OLTs). All OLTs were performed without an extended international donor background. The proportion of ALF among the indications for OLT was lower (5.8% vs 9%) and early mortality higher than the European Liver Transplant Registry (1 year cumulative patients survival is 70% in ELTR vs 60% in the HU LT Program). The waiting time for a donor was longer than expected in the Eurotransplant community. Regarding postoperative complications, there was a higher incidence of initial poor function, bacterial infection, sepsis, and multiorgan failure. We conclude that ALF can be managed with reasonable results but requires an extended donor pool with an integrated international network to improve postoperative morbidity and mortality.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21620110     DOI: 10.1016/j.transproceed.2011.03.076

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  MARS therapy, the bridging to liver retransplantation - Three cases from the Hungarian liver transplant program.

Authors:  Balázs Pőcze; János Fazakas; Gergely Zádori; Dénes Görög; László Kóbori; Eszter Dabasi; Tamás Mándli; László Piros; Anikó Smudla; Tamás Szabó; Eva Toronyi; Szabolcs Tóth; Gellért Tőzsér; Gyula Végső; Attila Doros; Balázs Nemes
Journal:  Interv Med Appl Sci       Date:  2013-07-04

2.  Liver transplantation in Central Europe.

Authors:  Pavel Trunecka; Zsuzsanna Gerlei; Wojciech Lisik; Lubomir Skladany; Jiri Fronek; Stefan Hrusovsky; Piotr Małkowski
Journal:  Clin Exp Hepatol       Date:  2016-03-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.